Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
Researchers removed individual components from mRNA-LNP formulations to distinguish the contributions of ionizable lipid, cholesterol, phospholipid, and PEG-lipid. Animal experiments linked these components differently to liver delivery, extrahepatic expression, particle size, and inflammation. The results challenge uniform assumptions about helper-lipid functions, while remaining dependent on the specific formulations and experimental systems tested in this study.
Chugai reported that AQUA07, its third macrocyclic peptide project, had entered the clinical stage, with Phase 1 dosing in ALK-positive non-small cell lung cancer expected shortly. Its pipeline identifies AQUA07 as an oral allosteric ALK inhibitor originating from SnipeTide. The milestone does not establish that human efficacy has already been demonstrated.
Nine bile-acid-derived sterols varied hydroxylation and alkyl-tail chemistry to probe LNP organization and organ expression. Molecular simulations and experiments linked membrane descriptors with encapsulation and formulation behavior. Replacing cholesterol shifted expression toward the spleen, and a lead sterol enhanced antigen-specific responses. The work offers a preclinical formulation framework rather than validated prediction of human biodistribution.
Immunomic announced first-patient dosing in VITALITI, the first-in-human Phase 1 trial of ITI-5000, a self-amplifying RNA cancer vaccine. The open-label study evaluates safety, tolerability, and preliminary immune activity in stage II–III triple-negative breast cancer, alone or alongside standard adjuvant therapy. Initial monitoring of the first participant identified no significant safety concerns, but this milestone provides no efficacy evidence.
Bispecific antibodies were used to bridge PEG motifs on LNPs and selected cellular surface markers without elaborate chemical conjugation. The platform enabled targeted mRNA delivery in cell models and transferrin-receptor-associated delivery in vivo. Researchers also measured endosomal responses at different antibody-loading ratios. Splenic enrichment supports further immune-cell targeting studies, but does not establish a clinical delivery solution.
FDA approved LIPFENDRA, or enlicitide, on July 15, with Merck announcing the decision on July 16. The once-daily 20 mg oral macrocyclic PCSK9 inhibitor is indicated alongside diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH. Its approved lipid indication should not be conflated with product-specific proof of cardiovascular-event reduction.
A hollow-fiber membrane platform uses dense nanopore arrays to control localized mixing during lipid nanoparticle assembly. The continuous process generated tunable particle sizes, narrow distributions, and high encapsulation, with particle properties linked to membrane pore size. Multiple lipid chemistries and nucleic acid payloads were compatible, and cell and animal studies supported activity. Commercial GMP performance remains to be established.
Acid-cleavable cholesterol-derived crosslinkers and PEG-diamines stabilized anionic LNPs that otherwise lost activity during purification. By tuning crosslinking architecture, researchers balanced structural integrity with RNA release and improved splenic mRNA expression. Mechanistic analyses implicated intracellular processing as well as release behavior. These formulation-specific animal results do not establish general T-cell targeting or clinical manufacturing readiness.
This industry perspective examines native mass spectrometry as a complement to established biopharmaceutical characterization methods. It discusses intact assemblies, binding, stoichiometry, and heterogeneity, while identifying throughput, sensitivity, automation, and access limitations. The authors emphasize integration with analytical workflows rather than universal replacement of existing methods.
Tempest outlined TPST-4003, an in vivo CAR-T candidate using CD7-targeted mRNA/LNP delivery of a dual CD19/BCMA CAR. A planned investigator-initiated study would enroll approximately ten patients with nervous-system autoimmune diseases, initially including myasthenia gravis and multiple sclerosis, with dosing anticipated in the fourth quarter. This is a development plan, not human efficacy evidence for the in vivo candidate.
Hansoh granted Avere exclusive development, manufacturing, and commercialization rights to HS-20118, also called AVR-001, outside Greater China. The oral cyclic IL-23R antagonist agreement includes $120 million in upfront payments, up to $2.18 billion in milestones, and royalties. Avere also announced a proposed NextCure merger. Conditional milestone value and a signed merger agreement do not represent realized payments or closing.
A library of 56 ionizable lipids combined biodegradable disulfide linkages with different hydrophobic tail lengths and branching patterns. Structure-activity testing linked tail architecture to endosomal escape, translation, and biocompatibility. Optimized particles reduced cytotoxicity and cytokine induction, with immune-response evaluation extending to a nonhuman primate model. These findings support lipid design, rather than establishing human safety.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
